Sylvester Discusses Wave of Plaintiffs’ CBD-Level Lawsuits

07 October 2019 News

Special Counsel Brian Sylvester was quoted in the article, “Plaintiff’s Bar Turns Attention to CBD with Wave of Lawsuits Alleging Products Contain ‘Significantly Lower Levels’ Than Advertised,” about how the plaintiff’s bar has begun suing CBD product manufacturers over the level of CBD in their products. The suits claim that the CBD levels often are significantly lower than advertised on websites and labeling for the products.

Sylvester said the discrepancies were potentially a fertile ground for the plaintiff’s bar. “We’ve already heard from the FDA that as part of their regulatory enforcement activity (i.e., warning letters issues to firms that market unapproved new drugs that allegedly contain CBD), the FDA has tested the chemical content of cannabinoid compounds in some of the products, and many were found to not contain the levels of CBD they claimed to contain. Plaintiffs have taken note of these findings.”

Related Services